Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Gelb, J. Donohue, A. D‘Urzo, L. Rekeda, E. Garcia Gil, J. Lateiner (Lakewood, Chapel Hill, Jersey City, United States Of America; Toronto, Canada; Barcelona, Spain). ACCORD COPD I: Twice-daily aclidinium bromide improves quality of life and dyspnea in COPD patients. Eur Respir J 2011; 38: Suppl. 55, 876

Member's Comments

No comment yet.

Related content which might interest you: ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice-daily aclidinium bromide Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Twice-daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010 ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011 Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 NVA237 once daily improves dyspnea and health-related quality of life (HRQoL) in patients with COPD: The GLOW1 trial Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Once-daily QVA149 improves symptom scores in patients with COPD Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: A phase IIIb study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Aclidinium bromide improves symptoms and sleep quality in COPD: a pilot study Source: Eur Respir J, 49 (6) 1700485; 10.1183/13993003.00485-2017 Year: 2017 Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium Source: Eur Respir J 2002; 19: 209-216 Year: 2002 Pooled analysis of twice-daily aclidinium bromide in COPD patients: Dyspnea and health status in the ACCORD-COPD I and ATTAIN trials Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study Source: Eur Respir J 2014; 43: 1599-1609 Year: 2014 Indacaterol once-daily improves health-related quality of life in COPD patients: a 26-week comparison with placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009 Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 The effect of twice-daily aclidinium bromide on cough and sputum in patients with COPD: Results from phase III studies Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014